Compare Etsy Inc (ETSY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Summit Therapeutics Inc — how do they compare? Etsy Inc trades at $76.79 (market cap $6.90B), while Summit Therapeutics Inc trades at $17.54 (market cap $13.71B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Etsy Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and Summit Therapeutics Inc for 16 Days on average.
| ETSY | SMMT | |
|---|---|---|
Market Cap | $6.90B | $13.71B |
Volume | 2,923,867 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $26.38 |
52-Week Low | $44.05 | $12.43 |
Typical Hold Time | 67 Days | 16 Days |
Enterprise Value | $8.85B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $74.90, up 4.77% today, showing strong momentum after recent earnings beats. The stock is in a bullish technical trend with support at $73 and resistance at $76. Revenue reached $2.88B in 2025, with a net income margin of 5.65%. Recent news highlights AI integration and payment partnerships as growth catalysts, while analyst consensus remains positive with a $85.94 price target.
The outlook for ETSY is cautiously optimistic, supported by consistent earnings outperformance and strategic initiatives. Key risks include high debt levels and competitive e-commerce pressures. Upside potential exists if AI-driven personalization boosts user engagement, but investors should monitor margin sustainability and macroeconomic impacts on consumer spending.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
